X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Fresenius Kabi Onco. - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs FRESENIUS KABI ONCO. - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA FRESENIUS KABI ONCO. TORRENT PHARMA/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 29.3 22.1 132.2% View Chart
P/BV x 5.6 3.1 178.6% View Chart
Dividend Yield % 1.0 0.0 -  

Financials

 TORRENT PHARMA   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-17
FRESENIUS KABI ONCO.
Mar-13
TORRENT PHARMA/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs1,768176 1,004.4%   
Low Rs1,18679 1,510.3%   
Sales per share (Unadj.) Rs346.137.7 918.4%  
Earnings per share (Unadj.) Rs55.25.1 1,083.2%  
Cash flow per share (Unadj.) Rs73.36.7 1,090.4%  
Dividends per share (Unadj.) Rs14.000-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs257.142.5 604.2%  
Shares outstanding (eoy) m169.22158.23 106.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.33.4 126.4%   
Avg P/E ratio x26.825.0 107.1%  
P/CF ratio (eoy) x20.118.9 106.4%  
Price / Book Value ratio x5.73.0 192.1%  
Dividend payout %25.40-   
Avg Mkt Cap Rs m249,88720,135 1,241.1%   
No. of employees `00011.81.2 1,022.7%   
Total wages/salary Rs m9,934703 1,412.7%   
Avg. sales/employee Rs Th4,971.55,176.2 96.0%   
Avg. wages/employee Rs Th843.2610.4 138.1%   
Avg. net profit/employee Rs Th792.4699.6 113.3%   
INCOME DATA
Net Sales Rs m58,5695,963 982.2%  
Other income Rs m2,23318 12,405.6%   
Total revenues Rs m60,8025,981 1,016.6%   
Gross profit Rs m13,7731,430 963.1%  
Depreciation Rs m3,069258 1,190.1%   
Interest Rs m2,056-26 -7,906.2%   
Profit before tax Rs m10,8811,216 894.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m1,545342 451.5%   
Profit after tax Rs m9,336806 1,158.4%  
Gross profit margin %23.524.0 98.1%  
Effective tax rate %14.228.1 50.5%   
Net profit margin %15.913.5 117.9%  
BALANCE SHEET DATA
Current assets Rs m53,8415,102 1,055.4%   
Current liabilities Rs m31,6122,385 1,325.2%   
Net working cap to sales %38.045.6 83.3%  
Current ratio x1.72.1 79.6%  
Inventory Days Days97150 64.8%  
Debtors Days Days84113 73.9%  
Net fixed assets Rs m42,0795,148 817.4%   
Share capital Rs m846158 534.9%   
"Free" reserves Rs m42,6556,556 650.7%   
Net worth Rs m43,5016,732 646.2%   
Long term debt Rs m22,408952 2,353.3%   
Total assets Rs m101,25010,388 974.7%  
Interest coverage x6.3-45.8 -13.7%   
Debt to equity ratio x0.50.1 364.2%  
Sales to assets ratio x0.60.6 100.8%   
Return on assets %11.37.5 149.9%  
Return on equity %21.512.0 179.3%  
Return on capital %19.614.6 134.4%  
Exports to sales %074.5 0.0%   
Imports to sales %024.8 0.0%   
Exports (fob) Rs mNA4,441 0.0%   
Imports (cif) Rs mNA1,477 0.0%   
Fx inflow Rs m20,0665,298 378.8%   
Fx outflow Rs m5,3041,772 299.3%   
Net fx Rs m14,7623,525 418.7%   
CASH FLOW
From Operations Rs m10,1271,274 794.8%  
From Investments Rs m-7,869-1,204 653.5%  
From Financial Activity Rs m-1,918-196 978.1%  
Net Cashflow Rs m212-126 -167.5%  

Share Holding

Indian Promoters % 71.5 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 7.0 0.3 2,340.0%  
FIIs % 12.6 9.6 131.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 9.1 96.7%  
Shareholders   26,511 42,599 62.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   STERLING BIOTECH  PFIZER  ALEMBIC PHARMA  ORCHID PHARMA LTD  SANOFI INDIA  

Compare TORRENT PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Share Markets Open Flat; Yes Bank Top Gainer(09:30 am)

Asian stock markets are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 0.31% while the Hang Seng is up 0.07%. The Shanghai Composite is trading up by 0.35%.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Jan 19, 2018 10:43 AM

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 5-YR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS